Aizier – Chapelle Saint-Thomas

Identifiant de l'opération archéologique : 1405 Date de l'opération : 1999 - 2000 (FP) ; 1998 (SD) Présentation du site Le site d'Aizier est localisé en lisière de la forêt de Brotonne, sur la rive gauche de la Seine correspondant à la frange septentrionale du plateau Roumois. La première mention de la chapelle remonte à 1227, cependant ses caractéristiques architecturales et sa dédicace à saint Thomas-Becket permettent de proposer de la dater de la fin du XIIe s. au plus tôt. Les mentions co..

Haematologica

Not available

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study

BACKGROUND We recently reported that peroxisome proliferator‐activated receptor γ agonists target chronic myeloid leukemia (CML) quiescent stem cells in vitro by decreasing transcription of STAT5. Here in the ACTIM phase 2 clinical trial, we asked whether pioglitazone add‐on therapy to imatinib would impact CML residual disease, as assessed by BCR‐ABL1 transcript quantification. METHODS CML patients were eligible if treated with imatinib for at least 2 years at a stable daily dose, having yielded major molecular response (MMR) but not having achieved molecular response 4.5 (MR4.5) defined by BCR‐ABL1/ABL1 IS RNA levels ≤ 0.0032%. After inclusion, patients started pioglitazone at a dosage of 30 to 45 mg/day in addition to imatinib. The primary objective was to evaluate the cumulative incidence of patients having progressed from MMR to MR4.5 over 12 months. RESULTS Twenty‐four patients were included (age range, 24‐79 years). No pharmacological interaction was observed between the drugs. The main adverse events were weight gain in 12 patients and a mean decrease of 0.4 g/dL in hemoglobin concentration. The cumulative incidence of MR4.5 was 56% (95% confidence interval, 37%‐76%) by 12 months, despite a wide range of therapy duration (1.9‐15.5 months), and 88% of 17 evaluable patients who were still on imatinib reached MR4.5 by 48 months. The cumulative incidence of MMR to MR4.5 spontaneous conversions over 12 months was estimated to be 23% with imatinib alone in a parallel cohort of patients. CONCLUSION Pioglitazone in combination with imatinib was well tolerated and yielded a favorable 56% rate. These results provide a proof of concept needing confirmation within a randomized clinical trial (EudraCT 2009‐011675‐79). Cancer 2017;123:1791–1799. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes

Novel Naphthalene-Based Inhibitors of Trypanosoma brucei RNA Editing Ligase 1

African sleeping sickness is a devastating disease that plagues sub-Saharan Africa. Neglected tropical diseases like African sleeping sickness cause significant death and suffering in the world's poorest countries. Current treatments for African sleeping sickness either have high costs, terrible side effects, or limited effectiveness. Consequently, new medicines are urgently needed. RNA editing ligase 1 is an important protein critical for the survival of Trypanosoma brucei, the unicellular parasite that causes African sleeping sickness. In this paper, we describe our recent efforts to use advanced computer techniques to identify chemicals predicted to prevent RNA editing ligase 1 from functioning properly. We subsequently tested our predicted chemicals and confirmed that a number of them inhibited the protein's function. Additionally, one of the chemicals was effective at stopping the growth of the parasite in culture. Although substantial work remains to be done in order to optimize these chemicals so they are effective and safe to use in human patients, the identification of these parasite-killing compounds is nevertheless a valuable step towards finding a better cure for this devastating disease

L'HOMEOPATHIE, MYTHE OU REALITE SCIENTIFIQUE ?

NANTES-BU Médecine pharmacie (441092101) / SudocSudocFranceF

Le Conseil officinal (champ d'action, état des lieux et perspectives)

RENNES1-BU Santé (352382103) / SudocLYON1-BU Santé (693882101) / SudocSudocFranceF

Measurement of the hydrogen bond acceptance of ionic liquids and green solvents by the 19 F solvatomagnetic comparison method

International audienceThe 19 F solvatomagnetic comparison method yields a more reliable scale (β1) of solvent hydrogen-bond acceptance than the solvatochromic comparison method. For [C4mim] based ionic liquids, the β1 order MeCO2 − (1.30) > Cl − (0.79) > NO3 − (0.67) > SCN − (0.64) > I − (0.44) > BF4 − (0.36) > PF6 − (0.27) is significantly correlated to the intrinsic hydrogen-bonding-, and even proton-, basicities of anions. For solvents of green interest, the β1 value of water is now settled down to 0.37, the newly determined value of limonene is 0.15, while those of α-pinene (0.14), glycerol (0.36), Cyrene TM (0.40), 2methyltetrahydrofuran (0.66), ethyl lactate (0.58), and γ-valerolactone (0.52) are found chemically more relevant than the solvatochromic ones

Concurrent and predictive validity of the Motor Functional Development Scale for Young Children in preterm infants

International audienceBackground: The Motor Functional Development Scale for Young Children (DF-mot) is a developmental tool assessing both gross and fine motor skills in term infants. Aims: To examine the concurrent validity of the DF-mot with the Alberta Infants Motor Scale (AIMS) in preterm infants and compare their ability in predicting scores on the Bayley Scales of Infant-Toddler Development (Bayley-III) at 12 months. Study design: Retrospective cohort study. Subjects and outcome measures: Hundred and eleven infants born at less than 32 weeks' gestation or with a birthweight less than 1500 g were assessed simultaneously on the DF-mot and the AIMS at age 3–5 months. Correlation analysis was used to determine the strength of association between the DF-mot and the AIMS. Among these, 62 were reassessed on the Bayley-III at age 9–12 months. Clinimetric properties were calculated to evaluate their ability to predict motor delay on the Bayley-III. Results: The concurrent validity study found a good level of correlation between the two scales (r = 0.79). The predictive validity study showed good sensitivity and negative predictive value for the AIMS 25th centile and the DF-mot -1 standard deviation to predict motor delay at 12 months (respectively Se = 100% and 84%; NPV = 100% and 77.8%). Conclusions: The DF-mot is a valid instrument with good predictive validity in preterm infants, suggesting it can be used as a clinical useful tool to assess motor development